Univercells Technologies Introduces the Scale-X Nexo Bioreactor for Enhanced Cell Culture Process Development
Univercells Technologies by Donaldson has launched the scale-X nexo bioreactor, a new addition to its scale-X portfolio, designed to support efficient cell culture process development across multiple modalities.
The scale-X nexo bioreactor, the smallest unit in the scale-X family, is designed with scalability in mind, offering a 0.5 m² growth surface to facilitate early-stage research and process optimization.
It is compatible with larger models, such as the scale-X carbo (10–30 m²) and scale-X nitro (200–600 m²), with the goal of maintaining consistency in cell distribution and achieving high cell densities at various scales.
Scale-X Nexo
Key features of the scale-X nexo bioreactor:
- Scalability: Designed to ensure smooth scalability from the nexo to larger bioreactors within the scale-X portfolio.
- Cost efficiency: Aims to reduce media and reagent consumption, targeting up to a 60% reduction in cost per run compared to other entry-level fixed-bed bioreactors.
- Versatility: Ready-to-use manifolds for rapid setup, designed to support a range of applications, including cell and gene therapies and vaccines.
Marie Jourdan, Director of the Bioprocess Product Portfolio at Donaldson, said:
“The scale-X nexo bioreactor is intended to assist research institutions and biopharma companies in early-stage development by helping them optimize cell density and process conditions efficiently.”
The bioreactor also integrates with the Skaia vision application, a software designed to estimate cell numbers within the bioreactor without direct sampling, with the goal of enhancing operational efficiency.
Live demonstrations of the scale-X technology will be available at ESGCT in Rome, October 22–25, 2024, at the Donaldson Life Sciences Booth #E21.
Topics: Tools & Methods
